Van Aerts et al1 report in this issue of Gastroenterology that the somatostatin analogue lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease. Their study substantiates the 2 previous placebo-controlled, randomized trials from Europe and the United States, that somatostatin analogues have a beneficial effect on liver volume growth in patients with polycystic liver disease (PCLD).2,3 The present study that includes 175 patients, offers additional robust evidence of the efficacy of lanreotide for this indication.